29 research outputs found
ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer
Radiation therapy (RT) is a valuable component of multimodal treatment for localized pancreatic cancer.
Intraoperative radiation therapy (IORT) is a very precise RT modality to intensify the irradiation effect for
cancer involving upper abdominal structures and organs, generally delivered with electrons (IOERT).
Unresectable, borderline and resectable disease categories benefit from dose-escalated chemoradiation
strategies in the context of active systemic therapy and potential radical surgery. Prolonged preoperative
treatment may act as a filter for selecting patients with occult resistant metastatic disease. Encouraging
survival rates have been documented in patients treated with preoperative chemoradiation followed by
radical surgery and IOERT (>20 months median survival, >35% survival at 3 years). Intensive preoperative
treatment, including induction chemotherapy followed by chemoradiation and an IOERT boost, appears
to prolong long-term survival within the subset of patients who remain relapse-free for>2 years
(>30 months median survival; >40% survival at 3 years). Improvement of local control through higher
RT doses has an impact on the survival of patients with a lower tendency towards disease spread.
IOERT is a well-accepted approach in the clinical scenario (maturity and reproducibility of results), and
extremely accurate in terms of dose-deposition characteristics and normal tissue sparing. The technique
can be adapted to systemic therapy and surgical progress. International guidelines (National
Comprehensive Cancer Network or NCCN guidelines) currently recommend use of IOERT in cases of close
surgical margins and residual disease. We hereby report the ESTRO/ACROP recommendations for performing IOERT in borderline-resectable pancreatic cancer
A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer
<p>Abstract</p> <p>Background</p> <p>Insufficient migration and activation of tumor specific effector T cells in the tumor is one of the main reasons for inadequate host anti-tumor immune response. External radiation seems to induce inflammation and activate the immune response. This phase I/II clinical trial aims to evaluate whether low dose single fraction radiotherapy can improve T cell associated antitumor immune response in patients with colorectal liver metastases.</p> <p>Methods/Design</p> <p>This is an investigator-initiated, prospective randomised, 4-armed, controlled Phase I/II trial. Patients undergoing elective hepatic resection due to colorectal cancer liver metastasis will be enrolled in the study. Patients will receive 0 Gy, 0.5 Gy, 2 Gy or 5 Gy radiation targeted to their liver metastasis. Radiation will be applied by external beam radiotherapy using a 6 MV linear accelerator (Linac) with intensity modulated radiotherapy (IMRT) technique two days prior to surgical resection. All patients admitted to the Department of General-, Visceral-, and Transplantion Surgery, University of Heidelberg for elective hepatic resection are consecutively screened for eligibility into this trial, and written informed consent is obtained before inclusion. The primary objective is to assess the effect of active local external beam radiation dose on, tumor infiltrating T cells as a surrogate parameter for antitumor activity. Secondary objectives include radiogenic treatment toxicity, postoperative morbidity and mortality, local tumor control and recurrence patterns, survival and quality of life. Furthermore, frequencies of systemic tumor reactive T cells in blood and bone marrow will be correlated with clinical outcome.</p> <p>Discussion</p> <p>This is a randomized controlled patient blinded trial to assess the safety and efficiency of low dose radiotherapy on metastasis infiltrating T cells and thus potentially enhance the antitumor immune response.</p> <p>Trial registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01191632">NCT01191632</a></p
Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer
<p>Abstract</p> <p>Background</p> <p>The efficiencies of T cell based immunotherapies are affected by insufficient migration and activation of tumor specific effector T cells in the tumor. Accumulating evidence exists on the ability of ionizing radiation to modify the tumor microenvironment and generate inflammation. The aim of this phase I/II clinical trial is to evaluate whether low dose single fraction radiotherapy can improve T cell associated antitumor immune response in patients with pancreatic cancer.</p> <p>Methods/Design</p> <p>This trial has been designed as an investigator initiated; prospective randomised, 4-armed, controlled Phase I/II trial. Patients who are candidates for resection of pancreatic cancer will be randomized into 4 arms. A total of 40 patients will be enrolled. The patients receive 0 Gy, 0.5 Gy, 2 Gy or 5 Gy radiation precisely targeted to their pancreatic carcinoma. Radiation will be delivered by external beam radiotherapy using a 6 MV Linac with IMRT technique 48 h prior to the surgical resection. The primary objective is the determination of an active local external beam radiation dose, leading to tumor infiltrating T cells as a surrogate parameter for antitumor activity. Secondary objectives include local tumor control and recurrence patterns, survival, radiogenic treatment toxicity and postoperative morbidity and mortality, as well as quality of life. Further, frequencies of tumor reactive T cells in blood and bone marrow as well as whole blood cell transcriptomics and plasma-proteomics will be correlated with clinical outcome. An interim analysis will be performed after the enrolment of 20 patients for safety reasons. The evaluation of the primary endpoint will start four weeks after the last patient's enrolment.</p> <p>Discussion</p> <p>This trial will answer the question whether a low dose radiotherapy localized to the pancreatic tumor only can increase the number of tumor infiltrating T cells and thus potentially enhance the antitumor immune response. The study will also investigate the prognostic and predictive value of radiation-induced T cell activity along with transcriptomic and proteomic data with respect to clinical outcome.</p> <p>Trial registration</p> <p>ClinicalTrials.gov - <a href="http://www.clinicaltrials.gov/ct2/show/NCT01027221">NCT01027221</a></p
Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT)
Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy
ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies
Item does not contain fulltex
ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer
Radiation therapy (RT) is a valuable component of multimodal treatment for localized pancreatic cancer.
Intraoperative radiation therapy (IORT) is a very precise RT modality to intensify the irradiation effect for
cancer involving upper abdominal structures and organs, generally delivered with electrons (IOERT).
Unresectable, borderline and resectable disease categories benefit from dose-escalated chemoradiation
strategies in the context of active systemic therapy and potential radical surgery. Prolonged preoperative
treatment may act as a filter for selecting patients with occult resistant metastatic disease. Encouraging
survival rates have been documented in patients treated with preoperative chemoradiation followed by
radical surgery and IOERT (>20 months median survival, >35% survival at 3 years). Intensive preoperative
treatment, including induction chemotherapy followed by chemoradiation and an IOERT boost, appears
to prolong long-term survival within the subset of patients who remain relapse-free for>2 years
(>30 months median survival; >40% survival at 3 years). Improvement of local control through higher
RT doses has an impact on the survival of patients with a lower tendency towards disease spread.
IOERT is a well-accepted approach in the clinical scenario (maturity and reproducibility of results), and
extremely accurate in terms of dose-deposition characteristics and normal tissue sparing. The technique
can be adapted to systemic therapy and surgical progress. International guidelines (National
Comprehensive Cancer Network or NCCN guidelines) currently recommend use of IOERT in cases of close
surgical margins and residual disease. We hereby report the ESTRO/ACROP recommendations for performing IOERT in borderline-resectable pancreatic cancer